Saturday, December 6th, 2014

Session: 618. Acute Lymphoblastic Leukemia:

Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I

Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies

Time / Loc.: 5:30-7:30 p.m. PT / North Building, Hall E

Abstract Number: 1072

Collaborator: Memorial Sloan Kettering Cancer Center

 

Session: 641. CLL:

Biology and Pathophysiology, excluding Therapy: Poster I

Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression

Time / Loc.: 5:30-7:30 p.m. PT / West Building, Level 1

Abstract Number: 1954

Collaborator: Memorial Sloan Kettering Cancer Center

 

Session: 617. Acute Myeloid Leukemia:

Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I

Utility of Combined DNA and RNA Next-Generation Sequencing in Leukemias for Identification of Prognostic and Therapeutically Relevant Genomic Alterations in Clinical Practice

Time / Loc.: 5:30-7:30 p.m. PT / North Building, Hall E

Abstract Number: 1039

Collaborator: Memorial Sloan Kettering Cancer Center

 

 

z

Session: 622. Non-Hodgkin Lymphoma:

Biology, excluding Therapy: Poster I

Genomic Alterations of Histone Modification Genes Are Significantly Less Common in Non-Hodgkin Lymphomas of Adolescents and Young Adults Compared to Older Patients

Time / Loc.: 5:30-7:30 p.m. PT / West Building, Level 1

Abstract Number: 1684

 

Session: 622. Non-Hodgkin Lymphoma:

Biology, excluding Therapy: Poster I

Comprehensive Hybrid Capture-Based Genomic Profiling of T-cell Leukemias and Lymphomas Reveals Targetable JAK1 and JAK3 Co-Existing Mutations

Time / Loc.: 5:30-7:30 p.m. PT / West Building, Level 1

Abstract Number: 1672

Collaborator: Vanderbilt University Medical Center

 

 

Sunday, December 7th, 2014

Session: 622. Non-Hodgkin Lymphoma:

Biology, excluding Therapy: Poster II

Identification of Actionable Genetic Alterations Across Different Lymphoma Histologies Using a Comprehensive Next Generation Genomic Sequencing Clinical Assay

Time / Loc.: 6:00-8:00 p.m. PT / West Building, Level 1

Abstract Number: 3000

Collaborator: Memorial Sloan Kettering Cancer Center

 

Session: 622. Non-Hodgkin Lymphoma:

Biology, excluding Therapy: Poster II

Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma

Time / Loc.: 6:00-8:00 p.m. PT / West Building, Level 1

Abstract Number: 3033

Collaborator: Hackensack University Medical Center

 

 

Session: 622. Non-Hodgkin Lymphoma:

Biology, excluding Therapy: Poster II

A Comprehensive Clinical Next-Generation Sequencing-Based Assay Can Impact Hematopathologic Diagnosis in a Significant Subset of Patients with Hematologic Malignancies

Time / Loc.: 6:00-8:00 p.m. PT / West Building, Level 1

Abstract Number: 2984

Collaborator: Memorial Sloan Kettering Cancer Center

 

Session: 651. Myeloma:

Biology and Pathophysiology, excluding Therapy: Poster II

Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling

Time / Loc.: 6:00-8:00 p.m. PT / West Building, Level 1

Abstract Number: 3418

Collaborator: University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy

 

Monday, December 8th, 2014

618. Acute Lymphoblastic Leukemia:

Preclinical Models

Patient Derived Xenograft (PDX) Models Recapitulate the Genomic-Driver Composition of Acute Leukemia Samples

Time / Loc.: 7:45 a.m. PT / West Building, 3002-3004

Abstract Number: 286

Collaborator: Memorial Sloan Kettering Cancer Center

 

622. Non-Hodgkin Lymphoma:

Biology, excluding Therapy II

Genomic Profiling Combining DNA and RNA Analysis of 112 Formalin-Fixed Paraffin-Embedded Diffuse Large B Cell Lymphoma Specimens Identifies a High Frequency of Clinically Relevant Genomic Alterations

Time / Loc.: 6:30 p.m. PT / North Building, 120-125

Abstract Number: 704

Collaborator: Memorial Sloan Kettering Cancer Center

 

 

Session: 653. Myeloma:

Therapy, excluding Transplantation: Poster III

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Time / Loc.: 6:00-8:00 p.m. PT / West Building, Level 1

Abstract Number: 4775

Collaborator: University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy